Report error Found 238 Enz. Inhib. hit(s) with all data for entry = 13063
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 10nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair
TargetDNA damage-binding protein 1/Protein cereblon(Human)
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Oncopia Therapeutics, Inc. D/B/A/ Sk Life Science Labs
US Patent
Affinity DataIC50: 20nMAssay Description:The binding potency was determined using HTRF assay technology (Perkin Elmer). Compounds were serially diluted in DMSO and 0.2 μL volume was transfer...More data for this Ligand-Target Pair

















































